Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mass communication

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Mass communication. Displaying page 1 of 1.
    EudraCT Number: 2019-003524-20 Sponsor Protocol Number: BP41316 Start Date*: 2020-12-15
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and tolerability of RO7017773 in participant...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003775-39 Sponsor Protocol Number: F1D-MC_X311 Start Date*: 2008-10-29
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis
    Medical condition: patients with amyotrophic lateral sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004263-47 Sponsor Protocol Number: EMR200104-011 Start Date*: 2013-03-01
    Sponsor Name:Merck KGaA
    Full Title: Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) of adult onset
    Medical condition: Adult Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-016921-32 Sponsor Protocol Number: HSJD-OB-TRP Start Date*: Information not available in EudraCT
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and ...
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004008-20 Sponsor Protocol Number: IPI-145-06 Start Date*: 2014-01-13
    Sponsor Name:Verastem, Inc.
    Full Title: A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma.
    Medical condition: Refractory Indolent Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029627 Non-Hodgkin's lymphoma unspecified histology intermediate grade refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-023534-23 Sponsor Protocol Number: EMR 200061-504 Start Date*: 2011-05-09
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A phase IIIB, multicentre, multinational, randomized, open-label trial to compare the efficacy and safety of ovarian stimulation with GONAL-f® day 1 to day 5 followed by Pergoveris® starting day 6 ...
    Medical condition: Fertility disorders
    Disease: Version SOC Term Classification Code Term Level
    12.1 10016398 Female infertility LLT
    12.1 10016399 Female infertility (primary) LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) FI (Completed) GB (Completed) DK (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002159-24 Sponsor Protocol Number: 54861911ALZ2002 Start Date*: 2014-10-27
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects in the Early (Predementia) Alzheime...
    Medical condition: Early Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000082-72 Sponsor Protocol Number: RC-P0054 Start Date*: 2019-01-03
    Sponsor Name:Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)
    Full Title: Study of the communication of the hypothalamus with the periphery: impact of metformin on leptin transport in the cerebrospinal fluid of obese patients. A monocentric prospective study
    Medical condition: OBESITY (BMI > 30)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003817-16 Sponsor Protocol Number: EMR200061-005 Start Date*: 2014-02-05
    Sponsor Name:Merck KGaA
    Full Title: A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris® (follitropin alfa and lutropin alfa) and GONAL-f® (follitropin...
    Medical condition: Poor Ovarian Response i.e. a failure to respond adequately to standard ART (assisted reproductive technologies) protocols and to recruit adequate follicles
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004872 10033140 Ovarian disorder NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) SE (Completed) EE (Completed) HU (Completed) BE (Completed) GB (Completed) NL (Completed) DK (Completed) LV (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004634-26 Sponsor Protocol Number: 4896 Start Date*: 2015-05-20
    Sponsor Name:Royal Liverpool University Hospital [...]
    1. Royal Liverpool University Hospital
    2. Liverpool School of Tropical Medicine
    Full Title: The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study
    Medical condition: Pneumococcal colonisation post inoculation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004920-40 Sponsor Protocol Number: AFFECT Start Date*: 2021-03-22
    Sponsor Name:Vestre Viken HF
    Full Title: Affective effects of pre-surgery opioids (AFFECT): a randomized double-blind controlled trial
    Medical condition: Healthy adult surgery patients. Health status ASA1 or ASA2 as categorised by a medical doctor at the hospital based on medical history, physical examination. The American Society of Anesthesiologis...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001254-29 Sponsor Protocol Number: I2R-MC-BIAM Start Date*: 2012-01-24
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAM The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, R...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Completed) LT (Completed) GR (Completed) IT (Completed) DK (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2010-021884-34 Sponsor Protocol Number: PERS3 Start Date*: 2013-01-24
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: Relapse prevention in children and adolescents with DSM-IV Conduct Disorder treated with Risperidone: a Randomized Double blind, Placebo-Controlled, Discontinuation Study.
    Medical condition: Conduct Disorder DSM-IV-TR; 312.8x, APA 2000
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064478 Conduct disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003159-12 Sponsor Protocol Number: J4B-MC-OKAA Start Date*: 2021-12-24
    Sponsor Name:Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
    Medical condition: Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004648-27 Sponsor Protocol Number: MS200569_0003 Start Date*: 2022-03-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, Randomized, Double-Blind, Placebo Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous ...
    Medical condition: Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057903 Subacute cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002527-21 Sponsor Protocol Number: AMYPAD-01 Start Date*: 2018-05-23
    Sponsor Name:University of Geneva
    Full Title: Multicentre, Open-label, Randomised Study to Assess the Diagnostic Value of Amyloid PET Imaging in Patients with Subjective Cognitive Decline Plus, Mild Cognitive Impairment, or Dementia Where Alzh...
    Medical condition: Alzheimer's disease Mild Cognitive Impairment Subjective Cognitive Decline Plus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 23:07:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA